My impression was the reason they sent this out was because share price is so low. They did their comparisons in the flier to NAV rather than PPS. I thought they were trying to show value. I guess we will see tomorrow what they report. But my guess is the report will be OK.
Hopefully CFO Penna will look into it. I hope the transition at IPCI now is CFO Penna runs the business side which will leave the Odidi's to their area of expertise which is drug formulations.
Clarification that no dilution for a good while is good news for longs. I personally did not expect any updates on PH3 data. The next thing we will likely hear on that is when they publish top line results.
So what do you think they used to secure this line of credit? They have no revenue. The terms for first year or two are interest only payments. I can only think of two things they have of value- Aldox and the new conjugate. Any opinions on this would be appreciated.
telmeafbl- I know you have been stressed out by the action here, but hopefully PH3 trial comes in with good results. If that happens, everything will be looking great for CYTR. Of course. I cannot guarantee results will be good, but I am optimistic based on many things.
I have to believe management knows what the results of this trial will be by now. I personally believe financing is good sign. The rate is high but is in line with rates given to companies that have no income and no real collateral other than the IP/potential of the products they are working on.
The idea I thought of was start out with a lower dosage version of the drug(where multiple would not be an overdose). Then compare blood levels of a person that has taken one and say five. That I believe would be a good conceptual test for starters. I don't know how they could test higher dosages. But maybe the experts at the FDA have a recommendation on this.
I do think this is the year for Rexista. Lots of stars lining up like government pressure for abuse deterrent opiods, Purdue litigation resolving and lastly they are nearly ready to file the NDA. Then we have the backlog of ANDAs. I would not be surprised to hear a few ANDA approvals this year as well.
Actually, although I was suspect, I think he is just a frustrated long that is down a lot on his investment. I am sure he had hoped that going into data the PPS would rise. But with market conditions, that is not happening. It can make one wonder if the price reflects the PH3 trial going bad??? Although I do not believe that to be the case, I now understand how he could feel that way- especially if he has a lot tied up in CYTR.